From a technical perspective, Dynavax Technologies ripped to the upside on Monday and broke out above some key overhead resistance levels at $23.87 to $24.60 with strong upside volume flows. This high-volume breakout is now quickly pushing shares of Dynavax Technologies within range of triggering another major breakout trade, which will trigger if this stock manages to clear Monday's intraday high of $25.53 and then once it takes out its 52-week high of $26.89 with high volume.
Traders should now look for long-biased trades in Dynavax Technologies as long as it's trending above those recent breakout levels at $24.60 or right around $24 to $23 and then once it sustains a move or close above $25.53 to $26.89 with volume that hits near or above 379,113 shares. If that breakout hits soon, then this stock will set up to enter new 52-week-high territory above $26.89, which is bullish technical price action. Some possible upside targets off that move are $30 to $35 a share.
The currently licensed hepatitis B vaccines have limitations including hyporesponsiveness in older adults, poor compliance, and the extended time for most persons to develop seroprotection (e.g. 6months). A vaccine containing HBsAg combined with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) has been developed to overcome these limitations.
A Phase 3, multicenter, randomized, subject- and observer-blinded, active-controlled trial was conducted among healthy subjects 40-70years of age comparing the immunogenicity and safety of two doses of HBsAg-1018 at 0 and 4weeks to three doses of licensed hepatitis B vaccine, HBsAg-Eng, at 0, 4, and 24weeks. The primary immunogenicity endpoint was noninferiority of the seroprotection rate (SPR; % with anti-HBs≥10mIU/mL) of HBsAg-1018 compared to the SPR of HBsAg-Eng at 8 weeks following the last dose of vaccine. Conditional upon meeting noninferiority, superiority of HBsAg-1018 over HBsAg-Eng was assessed. Safety was compared between the two vaccines.
At the primary endpoint, the SPR for the HBsAg-1018 group (90.0%) was superior to the SPR for the HBsAg-Eng group (70.5%) with an SPR difference of 19.5% (95% CI, 14.7%, 24.7%). At week 28 when the SPR peaked in the HBsAg-Eng group (72.8%), the SPR in the HBsAg-1018 group (94.8%) was significantly higher than in the HBsAg-Eng group. The SPR in the HBsAg-1018 group was significantly higher than in the HBsAg-Eng group at each study visit from week 4 through week 52. The safety profiles for the two vaccines were similar.
When compared to the HBsAg-Eng three-dose regimen given at 0, 1, and 6months, HBsAg-1018 demonstrated superior seroprotection with only two doses at 0 and 1month. The safety profile of HBsAg-1018 was comparable to that of the licensed vaccine, HBsAg-Eng. HBsAg-1018 would provide a significant public health contribution toward the prevention of hepatitis B infection.
It's all good,
Like you I'm long the company because I do believe in the science and its potential.
It's been my contention that posters show at strategic times to shuffle the deck if you will for the purpose of making a profit off of Fear or ignorance of other people. It would be naive to think there aren't those among us or that you might appear guilty be association.
This is some of your better TA work
Only Racism in DVAX is from the Neegras
dvaxtruth by dvaxtruth • Jul 31, 2013 6:14 AM Flag
Neegras causing the race card issue in DVAX. How many neegras you need to prove a drug works on them too?
The "Saggy Hooter" candle formation on the 15 Minute charts.
by dvaxtruth •Oct 23, 2013 1:25 PM
dvaxtruth dvaxtruth • Oct 23, 2013 1:31 PM Flag
Of course, there is always another possibility. Maybe the MM controlling this is a gaaaaybo. In which case, the "Limp Pencil Rick" formation is suggested.
15 Min "Jenna Jameson" candle formation.
dvaxtruth by dvaxtruth • Oct 29, 2013 11:11 AM Flag
Better look. The 15 minute charts are showing the "I just saw a Jenna Jameson movie" candle formation on the 15 min charts. This one could explode!
dvaxtruth by dvaxtruth • Nov 18, 2013 9:03 AM Flag
Fastbetty Nov 25, 2014 4;28 PM
Day trader trying to Scam your money away.
Oh right they are here everyone......right.....
For every dollar made in the Market there has to be a dollar lost. The scammers need the volume, your volume. They need freash money,your money. They need enough 'traders' to make the self fulfilling prophecy of charts work. Do you really think you can get your money out ahead of them and their high frequency trades?
Plus they have access to info you don't have.
Day trader pumpers.....
This was the question
Reply to Jim. Are you seeing a block at between $23.06 to $23.12 that's going to have to be gapped over? by dvaxtruth •20 hours ago
outboard.jack • 17 hours ago Remove 1users liked this postsusers disliked this posts1Reply
Did " You " post that buy ?
You only posted (Your sale) Not ( Your Buy )
If we are to assume you bought at the low why post your sell only ?
Shouldn't we assume you sold at the top.
I give up
there is no buy post
just like the 18 " handle " it has a + - of .99 cents
To much Grey area for me .
Jim needs to be right and that's cool
Good post Truth
I was in a fishing tournament on a stretch of river that was catch and release. To verify your fish you must take a picture of your catch against a measuring tape, one fellow brought in a photo that started at the midsection of the fish. So where did it start? No way to verify. Clearly This guy would not cheat I know him very well
Yet his fish was disqualified for non-verification.
Reply to Sharing some food for thought from Jimmygojames (Master chart reader)...by barryright519 •Apr 24, 2015 10:43 AM
outboard.jack outboard.jack • May 11, 2015 9:40 AM Remove Flag1 users liked this posts users disliked this posts 0 Reply
The short interest has been going up ( Your sellers ) With ( Scared or weak Retail ) as the institutions share has been rising ( your buyers with the traders ).
A lot of the selling is short as to fill the coffers with contract shares.
These shares are now selling at a strike price in blocks.
Katherine Xu expects Dynavax to release top-line data from the HBV-23 study towards the end of 2015. HBV-23 is a Phase 3 study on HEPLISAV, a pipeline vaccine for adults with hepatitis B. This is the final study for the drug, which investors hope will help clear the way for FDA approval in the United States. Xu is 90% confident the study will be successful and 80% confident the drug will be approved in the United States. The analyst estimates the data release from the study will have a fairly significant impact on the stock because “the market is already relatively confident in the success of the study.” Peak sales of the drug are expected to reach $600 million.
Aside from HEPLISAV, Xu also believes SD-101 is worth noting. SD-101 is an immune-oncology drug in Dynavax’s pipeline. The drug is currently is five Phase I/II studies and could produce meaningful data in 2016. If the data is “positive and promising,” Xu believes that SD-101 could be a much “bigger” product than HEPLISAV. The analyst provided commentary on the general stock and concluded, “Dynavax has a cash runway through mid-2016, and might need to raise financing in the near term.”
Y Katherine Xu currently an Outperform rating on DVAX with a $42 price target